LAWRENCE G. RAISZ, M.D.; CHAITANYA H. YAJNIK, M.D.; RICHARD S. BOCKMAN, M.D.; BRUCE F. BOWER, M.D.
This content is PDF only. Please click on the PDF icon to access.
The measurement of immunoreactive parathyroid hormone (iPTH) has become an important part of the differential diagnosis of hypercalcemia. High values in the absence of renal failure are considered diagnostic of primary hyperparathyroidism. It has been suggested that the finding of normal iPTH in the presence of elevated serum calcium concentration also should be considered diagnostic of primary hyperparathyroidism, on the assumption that iPTH should be suppressed if hypercalcemia were due to another cause (1, 2). However, normal or even somewhat elevated iPTH values have been reported in patients with hypercalcemia due to malignancy (3, 4). These values have been ascribed
RAISZ LG, YAJNIK CH, BOCKMAN RS, et al. Comparison of Commercially Available Parathyroid Hormone Immunoassays in the Differential Diagnosis of Hypercalcemia Due to Primary Hyperparathyroidism or Malignancy. Ann Intern Med. 1979;91:739–740. doi: 10.7326/0003-4819-91-5-739
Download citation file:
Published: Ann Intern Med. 1979;91(5):739-740.
Endocrine and Metabolism, Fluid and Electrolyte Disorders, Nephrology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use